Skip to main content
OpenTrials
Completed

NCT Number: NCT03689361

Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.

investigators hypothesize that T2 * vein abnormalities are frequent and are specific to the migraine aura.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hôpital Pierre Paul Riquet - CHU de Toulouse

Toulouse, 31049, France

About this study

The diagnosis of migraine aura is now based solely on clinical criteria and the assertion of the diagnosis on these clinical criteria alone proves difficult in the acute phase. Added to this difficulty, the symptomatology of a migraine aura can sometimes be similar to that of a stroke, so a diagnosis can be poorly established, resulting in poor patient care. The possibility of making the positive diagnosis of migraine aura on a routine MRI sequence, T2 *, would be an important advance for the management of these patients

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 to 55 years
  • Admitted to the Neuro-Vascular Intensive Care Unit for Acute Focused Neurological Symptoms and MRI
  • less than 4 hours 30 minutes after onset of symptoms if symptoms persist during admission
  • less than two hours after the disappearance of symptoms if the patient arrives asymptomatic
  • Affiliated to a social protection scheme.
  • Having given their informed consent

Exclusion criteria

  • Patients with neurological signs pointing to vertebrobasilar localization (vertigo, diplopia) or with a disorder of consciousness
  • Presence of recent explanatory abnormalities on the MRI to make a diagnosis compatible with the initial neurological symptomatology (visible stroke in diffusion, cerebral hemorrhage, tumor, arteriovenous malformations).
  • Potential strong cause of stroke known or discovered at the arrival of the patient, in particular stenosis of a cervical or intracranial artery upstream of the cerebral zone may correspond to the symptoms and emboligenic heart disease type atrial fibrillation.
  • Pregnant women - Patients with a contraindication for MRI.
  • Patients benefiting from a system of legal protection (tutelage,

Treatment and study plan

MRI

Combination Product

Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion).

MRI control

Diagnostic Test

MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion)

telephone consultation

Other

telephone consultation

Primary outcomes

  1. frequency of the presence of visible brain vein abnormalities

    Time frame: Day 0

    visible brain vein abnormalities on T2 * sequences MRI ,

Secondary outcomes

  1. perfusion parameters

    Time frame: Day 0

    in MRI , Overall visual assessment: presence or absence of hypoperfusion (presence or not in each anterior, middle and posterior territory) each lobe: Frontal, Temporal, Parietal, Occipital)

  2. asymmetry of visualization of the 3 intracranial arteries in MRI

    Time frame: Day 0

    in MRI TOF

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Acronym: MARIE

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Sep 28, 2018
Registry last updated
Feb 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.